$ALLR
Allarity Therapeutics, Inc. Stock $allr

$allr Overview Financials Valuation SEC Filings Company Website

2024 Q1 Form 10-K Financial Statement

#000121390024020864 Filed on March 08, 2024

Income Statement

Concept	2024 Q1	2023 Q4	2023 Q2
Revenue	$0.00	$0.00	$0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin	$2.070M	$2.256M	$3.051M
YoY Change	-7.26%	0.49%	4.24%
% of Gross Profit
Research & Development	$2.170M	$2.614M	$1.105M
YoY Change	52.07%	177.79%	-21.18%
% of Gross Profit
Depreciation & Amortization	$2.000K	$9.000K	$9.000K
YoY Change	-80.0%	350.0%	-62.5%
% of Gross Profit
Operating Expenses	$4.240M	$4.879M	$4.156M
YoY Change	15.88%	53.14%	-4.0%
Operating Profit	-$4.240M		-$4.156M
YoY Change	15.88%		-14.17%
Interest Expense	$102.0K	$3.240M	$142.0K
YoY Change	10.87%	-10.22%	-70.17%
% of Operating Profit
Other Income/Expense, Net	$393.0K	$0.00	$1.776M
YoY Change	28.01%		-322.0%
Pretax Income	-$3.847M	-$1.639M	-$2.380M
YoY Change	14.77%	-47.82%	-48.85%
Income Tax	-$4.000K	$83.00K
% Of Pretax Income
Net Earnings	-$3.843M	-$1.722M	-$2.380M
YoY Change	14.65%	-44.49%	-48.89%
Net Earnings / Revenue
Basic Earnings Per Share	-$22.14		-$26.28
Diluted Earnings Per Share	-$22.14	-$0.34	-$26.28
COMMON SHARES
Basic Shares Outstanding	6.179M shares	4.559M shares	19.14M shares
Diluted Shares Outstanding	175.3K shares		372.4K shares

Balance Sheet

Concept	2024 Q1	2023 Q4	2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments	$312.0K	$222.0K	$420.0K
YoY Change	5.76%	-89.33%	-94.5%
Cash & Equivalents	$312.0K	$166.0K	$420.0K
Short-Term Investments		$56.00K
Other Short-Term Assets	$110.0K	$803.0K	$1.495M
YoY Change	-89.69%	-48.49%	34.44%
Inventory
Prepaid Expenses	$542.0K	$781.0K	$220.0K
Receivables
Other Receivables
Total Short-Term Assets	$2.295M	$1.971M	$3.686M
YoY Change	-22.62%	-60.33%	-63.44%
LONG-TERM ASSETS
Property, Plant & Equipment	$18.00K	$20.00K	$26.00K
YoY Change	-28.0%	-4.76%	-44.68%
Goodwill
YoY Change
Intangibles		$9.871M	$9.714M
YoY Change		3.37%	-24.17%
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$9.674M	$9.891M	$9.740M
YoY Change	-0.64%	3.29%	-25.72%
TOTAL ASSETS
Total Short-Term Assets	$2.295M	$1.971M	$3.686M
Total Long-Term Assets	$9.674M	$9.891M	$9.740M
Total Assets	$11.97M	$11.86M	$13.43M
YoY Change	-5.77%	-18.44%	-42.11%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$11.06M	$8.416M	$8.089M
YoY Change	71.47%	34.63%	45.62%
Accrued Expenses	$1.553M	$1.309M	$1.921M
YoY Change	-33.94%	-31.25%	58.5%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$350.0K
YoY Change	-100.0%	-100.0%
Long-Term Debt Due	$2.690M	$1.300M
YoY Change
Total Short-Term Liabilities	$18.01M	$14.17M	$12.67M
YoY Change	55.4%	26.24%	13.2%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$1.138M
YoY Change	-100.0%	-100.0%	10.38%
Other Long-Term Liabilities			-$50.00
YoY Change
Total Long-Term Liabilities	$432.0K	$0.00	$1.138M
YoY Change	-61.08%	-100.0%	10.37%
TOTAL LIABILITIES
Total Short-Term Liabilities	$18.01M	$14.17M	$12.67M
Total Long-Term Liabilities	$432.0K	$0.00	$1.138M
Total Liabilities	$18.44M	$14.61M	$14.15M
YoY Change	41.4%	15.48%	9.87%
SHAREHOLDERS EQUITY
Retained Earnings	-$98.29M	-$94.50M	-$88.28M
YoY Change	14.43%	14.48%	18.22%
Common Stock	$0.00	$0.00	$0.00
YoY Change		-100.0%	-100.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	-$6.471M	-$2.751M	-$723.0K
YoY Change
Total Liabilities & Shareholders Equity	$11.97M	$11.86M	$13.43M
YoY Change	-5.77%	-18.44%	-42.11%

Cashflow Statement

Concept	2024 Q1	2023 Q4	2023 Q2
OPERATING ACTIVITIES
Net Income	-$3.843M	-$1.722M	-$2.380M
YoY Change	14.65%	-44.49%	-48.89%
Depreciation, Depletion And Amortization	$2.000K	$9.000K	$9.000K
YoY Change	-80.0%	350.0%	-62.5%
Cash From Operating Activities	-$1.487M	-$1.672M	-$2.496M
YoY Change	-53.55%	-31.64%	-36.15%
INVESTING ACTIVITIES
Capital Expenditures
YoY Change
Acquisitions
YoY Change
Other Investing Activities		$0.00	$0.00
YoY Change
Cash From Investing Activities		$0.00	$0.00
YoY Change		-100.0%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	$1.380M	522.0K	2.865M
YoY Change	19.17%	-47.8%	-223.97%
NET CHANGE
Cash From Operating Activities	-$1.487M	-1.672M	-2.496M
Cash From Investing Activities		0.000	0.000
Cash From Financing Activities	$1.380M	522.0K	2.865M
Net Change In Cash	-$107.0K	-1.150M	369.0K
YoY Change	-94.76%	-21.45%	-105.93%
FREE CASH FLOW
Cash From Operating Activities	-$1.487M	-$1.672M	-$2.496M
Capital Expenditures
Free Cash Flow
YoY Change

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent		usd
CY2023	dei	Document Type DocumentType	10-K
CY2023	dei	Document Annual Report DocumentAnnualReport	true
CY2023	dei	Document Period End Date DocumentPeriodEndDate	2023-12-31
CY2023	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023	dei	Document Transition Report DocumentTransitionReport	false
CY2023	dei	Entity File Number EntityFileNumber	001-41160
CY2023	dei	Entity Registrant Name EntityRegistrantName	ALLARITY THERAPEUTICS, INC.
CY2023	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	87-2147982
CY2023	dei	Entity Address Address Line1 EntityAddressAddressLine1	24 School Street
CY2023	dei	Entity Address Address Line2 EntityAddressAddressLine2	2nd Floor
CY2023	dei	Entity Address City Or Town EntityAddressCityOrTown	Boston
CY2023	dei	Entity Address State Or Province EntityAddressStateOrProvince	MA
CY2023	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	02108
CY2023	dei	City Area Code CityAreaCode	(401)
CY2023	dei	Local Phone Number LocalPhoneNumber	426-4664
CY2023	dei	Security12b Title Security12bTitle	Common Stock, par value $0.0001 per share
CY2023	dei	Trading Symbol TradingSymbol	ALLR
CY2023	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2023	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2023	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023	dei	Entity Small Business EntitySmallBusiness	true
CY2023	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2023	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2023	dei	Document Fin Stmt Error Correction Flag DocumentFinStmtErrorCorrectionFlag	false
CY2023	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Public Float EntityPublicFloat	3323760	usd
CY2024Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	6178892	shares
CY2023	ecd	Non Rule10b51 Arr Adopted Flag NonRule10b51ArrAdoptedFlag	false
CY2023	ecd	Non Rule10b51 Arr Trmntd Flag NonRule10b51ArrTrmntdFlag	false
CY2023	ecd	Rule10b51 Arr Adopted Flag Rule10b51ArrAdoptedFlag	false
CY2023	ecd	Rule10b51 Arr Trmntd Flag Rule10b51ArrTrmntdFlag	false
CY2023	dei	Auditor Firm AuditorFirmId	392
CY2023	dei	Auditor Name AuditorName	Wolf & Company, P.C
CY2023	dei	Auditor Location AuditorLocation	Boston, MA
CY2023Q4	us-gaap	Cash Cash	166000	usd
CY2022Q4	us-gaap	Cash Cash	2029000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	209000	usd
CY2023	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	7103000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	6930000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	17571000	usd
CY2023	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	10026000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	9962000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1559000	usd
CY2023Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	781000	usd
CY2022Q4	us-gaap	Prepaid Expense Current PrepaidExpenseCurrent	591000	usd
CY2023Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	815000	usd
CY2022Q4	us-gaap	Income Taxes Receivable IncomeTaxesReceivable	789000	usd
CY2023Q4	us-gaap	Assets Current AssetsCurrent	1971000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	4968000	usd
CY2023Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	20000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	21000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	6000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	9871000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	9549000	usd
CY2023Q4	us-gaap	Assets Assets	11862000	usd
CY2022Q4	us-gaap	Assets Assets	14544000	usd
CY2023Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	8416000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	6251000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1309000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	1904000	usd
CY2023Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	3083000	usd
CY2022Q4	us-gaap	Derivative Liabilities Current DerivativeLiabilitiesCurrent	374000	usd
CY2023Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	59000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	41000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1300000	usd
CY2022Q4	us-gaap	Secured Debt Current SecuredDebtCurrent	2644000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	8000	usd
CY2023Q4	us-gaap	Liabilities Current LiabilitiesCurrent	14167000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	11222000	usd
CY2022Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable	1083000	usd
CY2023Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	446000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	349000	usd
CY2023Q4	us-gaap	Liabilities Liabilities	14613000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	12654000	usd
CY2022Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount	2003000	usd
CY2023Q4	us-gaap	Preferred Stock Value PreferredStockValue	1742000	usd
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	750000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	30000000	shares
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5886934	shares
CY2023Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	5886934	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	11356	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11356	shares
CY2023Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	90369000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	83158000	usd
CY2023Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-411000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	-721000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-94451000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-82550000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2751000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-113000	usd
CY2023Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11862000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	14544000	usd
CY2023	us-gaap	Operating Expenses OperatingExpenses	17129000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	34463000	usd
CY2023	us-gaap	Operating Income Loss OperatingIncomeLoss	-17129000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-34463000	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1780000	usd
CY2023	us-gaap	Investment Income Interest InvestmentIncomeInterest	22000	usd
CY2022	us-gaap	Investment Income Interest InvestmentIncomeInterest	30000	usd
CY2023	us-gaap	Interest Expense InterestExpense	498000	usd
CY2022	us-gaap	Interest Expense InterestExpense	223000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-115000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	133000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Before Tax ForeignCurrencyTransactionGainLossBeforeTax	-913000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4189000	usd
CY2023	allr	Loss On Modification Of Warrants LossOnModificationOfWarrants	591000	usd
CY2023	allr	Change In Fair Value Adjustment Of Warrant Derivative Liabilities ChangeInFairValueAdjustmentOfWarrantDerivativeLiabilities	-10434000	usd
CY2022	allr	Change In Fair Value Adjustment Of Warrant Derivative Liabilities ChangeInFairValueAdjustmentOfWarrantDerivativeLiabilities	-17125000	usd
CY2022	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments	800000	usd
CY2023	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	5311000	usd
CY2022	us-gaap	Nonoperating Income Expense NonoperatingIncomeExpense	16884000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11818000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17579000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1521000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11901000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16058000	usd
CY2022	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends	3421000	usd
CY2023	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments	8392000	usd
CY2023	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	123000	usd
CY2022	us-gaap	Preferred Stock Dividends Income Statement Impact PreferredStockDividendsIncomeStatementImpact	1572000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20416000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21051000	usd
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.26
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3093.42
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1990748	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6805	shares
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11901000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16058000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	310000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Transaction And Translation Adjustment Net Of Tax OtherComprehensiveIncomeLossForeignCurrencyTransactionAndTranslationAdjustmentNetOfTax	-121000	usd
CY2023	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-11591000	usd
CY2022	us-gaap	Comprehensive Income Net Of Tax ComprehensiveIncomeNetOfTax	-16179000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	18152000	usd
CY2022	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	203000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Other AdjustmentsToAdditionalPaidInCapitalOther	-3421000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	954000	usd
CY2022	allr	Deemed Dividend Percentage DeemedDividendPercentage	0.08	pure
CY2022	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	1572000	usd
CY2022	us-gaap	Dividends Preferred Stock DividendsPreferredStock	2000	usd
CY2022	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	1752000	usd
CY2022	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	-121000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16058000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-113000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-113000	usd
CY2023	allr	Deemed Dividend Percentage DeemedDividendPercentage	0.05	pure
CY2023	us-gaap	Stock Issued During Period Value Stock Dividend StockIssuedDuringPeriodValueStockDividend	164000	usd
CY2023	allr	Roundcommonsharesissued Roundcommonsharesissued	1-for-35
CY2023	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	1-for-40
CY2023	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1377000	usd
CY2023	allr	Stock Issued During Period Value Redemption Of Preferred Stock StockIssuedDuringPeriodValueRedemptionOfPreferredStock	2000	usd
CY2023	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	6815000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Warrant Issued AdjustmentsToAdditionalPaidInCapitalWarrantIssued	3772000	usd
CY2023	allr	Deemed Dividends On Series A Preferred Stock DeemedDividendsOnSeriesAPreferredStock	-123000	usd
CY2023	allr	Stock Issued During Period Value Eliminationof Series A Redemption Rights StockIssuedDuringPeriodValueEliminationofSeriesARedemptionRights	624000	usd
CY2023	allr	Stock Issued During Period Value Issuance Of A Preferred Stock As Repayment Of Debt StockIssuedDuringPeriodValueIssuanceOfAPreferredStockAsRepaymentOfDebt	453000	usd
CY2023	allr	Deemed Dividend On Redemption Of Cancellation Financing DeemedDividendOnRedemptionOfCancellationFinancing	-1652000	usd
CY2023	allr	Deemed Dividends Of Preferred Stock DeemedDividendsOfPreferredStock	1447000	usd
CY2023	us-gaap	Stock Issued During Period Value Other StockIssuedDuringPeriodValueOther	10080000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Mark To Market AdjustmentsToAdditionalPaidInCapitalMarkToMarket	-6254000	usd
CY2023	allr	Deemed Dividend On Redemption Of Conjunction Financing DeemedDividendOnRedemptionOfConjunctionFinancing	-5000000	usd
CY2023	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	2962000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Convertible Debt With Conversion Feature AdjustmentsToAdditionalPaidInCapitalConvertibleDebtWithConversionFeature	1056000	usd
CY2023	allr	Stock Issued During Period Value Cashless Exercise Of Exchange Warrants StockIssuedDuringPeriodValueCashlessExerciseOfExchangeWarrants	1031000	usd
CY2023	us-gaap	Adjustments To Additional Paid In Capital Share Based Compensation Stock Options Requisite Service Period Recognition AdjustmentsToAdditionalPaidInCapitalShareBasedCompensationStockOptionsRequisiteServicePeriodRecognition	71000	usd
CY2023	us-gaap	Other Comprehensive Income Loss Foreign Currency Translation Adjustment Tax OtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentTax	310000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11901000	usd
CY2023Q4	us-gaap	Stockholders Equity StockholdersEquity	-2751000	usd
CY2023	us-gaap	Net Income Loss NetIncomeLoss	-11901000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-16058000	usd
CY2022	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments	1780000	usd
CY2023	us-gaap	Depreciation And Amortization DepreciationAndAmortization	37000	usd
CY2022	us-gaap	Depreciation And Amortization DepreciationAndAmortization	60000	usd
CY2022	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived	17571000	usd
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	-71000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1752000	usd
CY2023	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	179000	usd
CY2022	us-gaap	Foreign Currency Transaction Gain Loss Unrealized ForeignCurrencyTransactionGainLossUnrealized	-450000	usd
CY2023	us-gaap	Paid In Kind Interest PaidInKindInterest	464000	usd
CY2022	us-gaap	Paid In Kind Interest PaidInKindInterest	138000	usd
CY2023	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense	-1110000	usd
CY2023	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	4189000	usd
CY2023	allr	Loss On Modification Of Warrants LossOnModificationOfWarrants	591000	usd
CY2022	us-gaap	Gain Loss On Investments GainLossOnInvestments	-115000	usd
CY2023	allr	Change In Fair Value Adjustment Of Warrant And Derivative Liabilities ChangeInFairValueAdjustmentOfWarrantAndDerivativeLiabilities	-10434000	usd
CY2022	allr	Change In Fair Value Adjustment Of Warrant And Derivative Liabilities ChangeInFairValueAdjustmentOfWarrantAndDerivativeLiabilities	-17125000	usd
CY2023	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	97000	usd
CY2022	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1612000	usd
CY2023	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	-1350000	usd
CY2022	us-gaap	Increase Decrease In Other Current Assets IncreaseDecreaseInOtherCurrentAssets	1077000	usd
CY2023	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable	26000	usd
CY2023	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	190000	usd
CY2022	us-gaap	Increase Decrease In Prepaid Expense IncreaseDecreaseInPrepaidExpense	618000	usd
CY2023	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	2165000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable IncreaseDecreaseInAccountsPayable	6207000	usd
CY2023	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	43000	usd
CY2022	us-gaap	Increase Decrease In Accrued Liabilities IncreaseDecreaseInAccruedLiabilities	-4722000	usd
CY2023	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	18000	usd
CY2022	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	-19000	usd
CY2023	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-8000	usd
CY2022	us-gaap	Increase Decrease In Other Operating Liabilities IncreaseDecreaseInOtherOperatingLiabilities	-99000	usd
CY2023	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-12745000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-16817000	usd
CY2022	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects	809000	usd
CY2022	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	18000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	791000	usd
CY2023	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	1160000	usd
CY2023	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1050000	usd
CY2022	us-gaap	Proceeds From Notes Payable ProceedsFromNotesPayable	1000000	usd
CY2023	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt	3699000	usd
CY2023	allr	Proceeds From Common Stock And Prefunded Warrant Issuance Net ProceedsFromCommonStockAndPrefundedWarrantIssuanceNet	16895000	usd
CY2023	allr	Proceeds From Warrants Exercised In Conjunction With Price Warrant Inducement ProceedsFromWarrantsExercisedInConjunctionWithPriceWarrantInducement	2243000	usd
CY2023	allr	Redemption Of Series A Preferred Stock RedemptionOfSeriesAPreferredStock	6652000	usd
CY2023	allr	Redemption Of Series B Preferred Stock RedemptionOfSeriesBPreferredStock	2000	usd
CY2022	allr	Cash Paid In Connection With Conversion Of Series A Preferred Stock CashPaidInConnectionWithConversionOfSeriesAPreferredStock	1511000	usd
CY2022	allr	Penalty On Series A Preferred Stock Liability PenaltyOnSeriesAPreferredStockLiability	800000	usd
CY2023	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	10995000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-1311000	usd
CY2023	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-1750000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Excluding Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseExcludingExchangeRateEffect	-17337000	usd
CY2023	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-113000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-189000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2029000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	19555000	usd
CY2023Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	166000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	2029000	usd
CY2023	us-gaap	Income Taxes Paid IncomeTaxesPaid	6000	usd
CY2022	us-gaap	Income Taxes Paid IncomeTaxesPaid	12000	usd
CY2023	us-gaap	Interest Paid Net InterestPaidNet	34000	usd
CY2022	us-gaap	Interest Paid Net InterestPaidNet	85000	usd
CY2022	allr	Gain On Sale Of Ip GainOnSaleOfIP	971000	usd
CY2023	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	3899000	usd
CY2022	us-gaap	Conversion Of Stock Amount Converted1 ConversionOfStockAmountConverted1	1157000	usd
CY2023	allr	Issuance Of Series A Preferred Stock In Exchange For Series C Preferred Stock IssuanceOfSeriesAPreferredStockInExchangeForSeriesCPreferredStock	5199000	usd
CY2023	allr	Issuance Of Series A Preferred Stock To Extinguish Promissory Note IssuanceOfSeriesAPreferredStockToExtinguishPromissoryNote	453000	usd
CY2023	allr	Redemption Of Series A Preferred Stock As Repayment Of Debt RedemptionOfSeriesAPreferredStockAsRepaymentOfDebt	1445000	usd
CY2023	allr	Deemed Dividend On Series A Preferred Stock DeemedDividendOnSeriesAPreferredStock	8392000	usd
CY2022	allr	Deemed Dividend On Series A Preferred Stock DeemedDividendOnSeriesAPreferredStock	1572000	usd
CY2023	allr	Deemed Dividend On Series C Convertible Preferred Stock And Accretion Of Series C Preferred Sh DeemedDividendOnSeriesCConvertiblePreferredStockAndAccretionOfSeriesCPreferredSh	123000	usd
CY2023	allr	Deemed Dividend On Exchange Of Series C Preferred Stock For Series A Preferred Stock DeemedDividendOnExchangeOfSeriesCPreferredStockForSeriesAPreferredStock	1031000	usd
CY2022	allr	Deemed Dividend On Redemption Of Series B Preferred Stock DeemedDividendOnRedemptionOfSeriesBPreferredStock	2000	usd
CY2022	allr	Conversion Of Floor Price Liability To Convertible Debt ConversionOfFloorPriceLiabilityToConvertibleDebt	1667000	usd
CY2022	allr	Reclassification Of Derivative Liabilities Related To Converted Preferred Stock ReclassificationOfDerivativeLiabilitiesRelatedToConvertedPreferredStock	954000	usd
CY2023Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-94500000	usd
CY2023Q4	us-gaap	Cash Cash	166000	usd
CY2023	us-gaap	Basis Of Accounting BasisOfAccounting	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>(a) Basis of Presentation</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The accompanying consolidated financial statements have been prepared on an accrual basis of accounting, in accordance with accounting principles generally accepted in the United States of America (“GAAP”). Any reference in these notes to applicable guidance is meant to refer to the authoritative GAAP as found in the ASC and Accounting Standards Updates (“ASU”) of the Financial Accounting Standards Board (“FASB”).</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 24pt"><span style="font-family: Times New Roman, Times, Serif"> </span></p>
CY2023	us-gaap	Use Of Estimates UseOfEstimates	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>(c) Use of Estimates</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities, the disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting years. Significant estimates and assumptions reflected in these consolidated financial statements include, but are not limited to, the fair value of the Series A preferred shares, warrants, 3i Exchange Warrants, convertible debt, and the accrual for research and development expenses, fair values of acquired intangible assets and impairment review of those assets, share based compensation expense, and income tax uncertainties and valuation allowances. The Company bases its estimates on historical experience, known trends and other market-specific or other relevant factors that it believes to be reasonable under the circumstances. Estimates are periodically reviewed considering reasonable changes in circumstances, facts, and experience. Changes in estimates are recorded in the period in which they become known and if material, their effects are disclosed in the notes to the consolidated financial statements. Actual results could differ from those estimates or assumptions.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>(d) Foreign currency and currency translation</i> </span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 35.45pt"><span style="font-family: Times New Roman, Times, Serif">The functional currency is the currency of the primary economic environment in which an entity’s operations are conducted. The Company and its subsidiaries operate mainly in Denmark and the United States. The functional currencies of the Company’s subsidiaries are their local currency.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">The Company’s reporting currency is the U.S. dollar. The Company translates the assets and liabilities of its Denmark subsidiaries into the U.S. dollar at the exchange rate in effect on the balance sheet date. Revenues and expenses are translated at the average exchange rate in effect during each monthly period. Unrealized translation gains and losses are recorded as a cumulative translation adjustment, which is included in the consolidated statements of changes in redeemable convertible preferred stock and stockholders’ equity as a component of accumulated other comprehensive loss.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Monetary assets and liabilities denominated in currencies other than the functional currency are remeasured into the functional currency at rates of exchange prevailing at the balance sheet dates. Non-monetary assets and liabilities denominated in foreign currencies are re-measured into the functional currency at the exchange rates prevailing at the date of the transaction. Exchange gains or losses arising from foreign currency transactions are included in the determination of net loss for the respective periods.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Adjustments that arise from exchange rate translations are included in other comprehensive income (loss) in the consolidated statements of operations and comprehensive loss as incurred. The Company recorded a foreign exchange translation gain (loss) of $309 and ($121), included in accumulated other comprehensive loss for the years ended December 31, 2023 and 2022, respectively.</span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 18pt; text-indent: -18pt"><span style="font-family: Times New Roman, Times, Serif"><i> </i></span></p>
CY2023	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><span style="font-family: Times New Roman, Times, Serif"><i>(e) Concentrations of credit risk and of significant suppliers</i></span></p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><span style="font-family: Times New Roman, Times, Serif">Financial instruments that potentially expose the Company to concentrations of credit risk consist primarily of cash. The Company maintains its cash in financial institutions in amounts that could exceed government-insured limits. The Company does not believe it is subject to additional credit risks beyond those normally associated with commercial banking relationships. The Company has not experienced losses on its cash accounts and management believes, based upon the quality of the financial institutions, that the credit risk regarding these deposits is not significant. The Company is dependent on third-party manufacturers to supply products for research and development activities in its programs. In particular, the Company relies and expects to continue to rely on a small number of manufacturers to supply its requirements for supplies and raw materials related to these programs. These programs could be adversely affected by a significant interruption in these manufacturing services or the availability of raw materials.</span></p>
CY2023Q4	allr	Depreciation Estimated Period depreciationEstimatedPeriod	P5Y
CY2023	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	0	usd
CY2022	us-gaap	Impairment Of Intangible Assets Indefinitelived Excluding Goodwill ImpairmentOfIntangibleAssetsIndefinitelivedExcludingGoodwill	17571000	usd
CY2023	us-gaap	Payments For Other Taxes PaymentsForOtherTaxes	5500000	dkk
CY2023Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	800000	usd
CY2022Q4	us-gaap	Tax Credit Carryforward Amount TaxCreditCarryforwardAmount	711000	usd
CY2023Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	56000	usd
CY2022Q4	us-gaap	Deposits Assets Current DepositsAssetsCurrent	51000	usd
CY2023Q4	allr	Salary Deposit SalaryDeposit	22000	usd
CY2022Q4	allr	Salary Deposit SalaryDeposit	85000	usd
CY2023Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	131000	usd
CY2022Q4	us-gaap	Value Added Tax Receivable Current ValueAddedTaxReceivableCurrent	82000	usd
CY2022Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent	81000	usd
CY2022Q4	allr	Deferred Directors Officers Insurance Expense Current DeferredDirectorsOfficersInsuranceExpenseCurrent	1260000	usd
CY2023Q4	us-gaap	Other Assets Current OtherAssetsCurrent	209000	usd
CY2022Q4	us-gaap	Other Assets Current OtherAssetsCurrent	1559000	usd
CY2022Q1	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	0.16	pure
CY2022Q1	us-gaap	Asset Impairment Charges AssetImpairmentCharges	14007000	usd
CY2022Q4	us-gaap	Percentage Of Weighted Average Cost Inventory PercentageOfWeightedAverageCostInventory	0.26	pure
CY2022	us-gaap	Asset Impairment Charges AssetImpairmentCharges	3564000	usd
CY2023Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	9871000	usd
CY2022Q4	us-gaap	Indefinite Lived Intangible Assets Excluding Goodwill IndefiniteLivedIntangibleAssetsExcludingGoodwill	9549000	usd
CY2023Q4	allr	Accrued Development Cost Liability AccruedDevelopmentCostLiability	114000	usd
CY2022Q4	allr	Accrued Development Cost Liability AccruedDevelopmentCostLiability	964000	usd
CY2023Q4	allr	Accruedinteresttonmilestoneliabilities Accruedinteresttonmilestoneliabilities	101000	usd
CY2023Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	398000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	221000	usd
CY2023Q4	allr	Accrued Board Member Fees AccruedBoardMemberFees	60000	usd
CY2022Q4	allr	Accrued Board Member Fees AccruedBoardMemberFees	91000	usd
CY2023Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent	150000	usd
CY2023Q4	allr	Accrued Audit And Legal AccruedAuditAndLegal	425000	usd
CY2022Q4	allr	Accrued Audit And Legal AccruedAuditAndLegal	239000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	61000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current And Noncurrent OtherAccruedLiabilitiesCurrentAndNoncurrent	389000	usd
CY2023Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1309000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current And Noncurrent AccruedLiabilitiesCurrentAndNoncurrent	1904000	usd
CY2022Q2	us-gaap	Debt Instrument Face Amount DebtInstrumentFaceAmount	1000000	usd
CY2023Q4	us-gaap	Deposit Liabilities Accrued Interest DepositLiabilitiesAccruedInterest	300000	usd
CY2023Q4	allr	Debt Instrument Current Liability DebtInstrumentCurrentLiability	1300000	usd
CY2023	us-gaap	Interest And Debt Expense InterestAndDebtExpense	217000	usd
CY2022	us-gaap	Interest And Debt Expense InterestAndDebtExpense	104000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1083000	usd
CY2021Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1000000	usd
CY2023Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	232000	usd
CY2022Q4	us-gaap	Debt Instrument Unamortized Discount Current DebtInstrumentUnamortizedDiscountCurrent	215000	usd
CY2023	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	51000	usd
CY2022	us-gaap	Interest Expense Long Term Debt InterestExpenseLongTermDebt	53000	usd
CY2023Q4	us-gaap	Convertible Debt ConvertibleDebt	889000	usd
CY2022Q4	us-gaap	Convertible Debt ConvertibleDebt	838000	usd
CY2023	us-gaap	Interest Expense Other InterestExpenseOther	245000	usd
CY2022	us-gaap	Interest Expense Other InterestExpenseOther	194000	usd
CY2023	us-gaap	Accretion Expense AccretionExpense	166000	usd
CY2022	us-gaap	Accretion Expense AccretionExpense	51000	usd
CY2023Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1300000	usd
CY2022Q4	us-gaap	Convertible Notes Payable ConvertibleNotesPayable	1083000	usd
CY2022Q3	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	350000	usd
CY2022Q4	us-gaap	Debt Instrument Carrying Amount DebtInstrumentCarryingAmount	650000	usd
CY2023Q4	us-gaap	Investment Maturity Date InvestmentMaturityDate	2024-01-01
CY2023	us-gaap	Proceeds From Other Debt ProceedsFromOtherDebt	5000000	usd
CY2023Q4	us-gaap	Financing Receivable Percent Past Due1 FinancingReceivablePercentPastDue1	0.35	pure
CY2023Q2	us-gaap	Notes And Loans Payable NotesAndLoansPayable	350000	usd
CY2023Q2	us-gaap	Deferred Offering Costs DeferredOfferingCosts	3348000	usd
CY2022Q4	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	9.906
CY2023Q2	us-gaap	Preferred Stock Redemption Amount PreferredStockRedemptionAmount	1652000	usd
CY2023Q2	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	1080
CY2023	allr	Accrued Percentage AccruedPercentage	0.18	pure
CY2023Q4	us-gaap	Financing Receivable Excluding Accrued Interest Nonaccrual Percent Past Due FinancingReceivableExcludingAccruedInterestNonaccrualPercentPastDue	0.18	pure
CY2023Q4	allr	Preferred Stock Redemption Percentage PreferredStockRedemptionPercentage	1.25	pure
CY2022Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Purchase Price Of Common Stock Percent SharebasedCompensationArrangementBySharebasedPaymentAwardPurchasePriceOfCommonStockPercent	0.02	pure
CY2022Q2	allr	Securities Purchase Agreement Percentage SecuritiesPurchaseAgreementPercentage	0.02	pure
CY2022Q2	us-gaap	Financing Receivable Excluding Accrued Interest Nonaccrual Percent Past Due FinancingReceivableExcludingAccruedInterestNonaccrualPercentPastDue	0.02	pure
CY2022Q2	allr	Accrue Payments Percent AccruePaymentsPercent	0.02	pure
CY2023Q4	us-gaap	Derivative Net Liability Position Aggregate Fair Value DerivativeNetLiabilityPositionAggregateFairValue	539000	usd
CY2022Q2	us-gaap	Derivative Net Liability Position Aggregate Fair Value DerivativeNetLiabilityPositionAggregateFairValue	539000	usd
CY2023Q2	allr	Warrant Exchange Shares WarrantExchangeShares	315085	shares
CY2023Q4	allr	Warrant Exchange Shares WarrantExchangeShares	4407201	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Exercise Price Of Warrants Or Rights1 ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1	1
CY2023	us-gaap	Financing Receivable Modification To Total Financing Receivables Percent FinancingReceivableModificationToTotalFinancingReceivablesPercent	0.10	pure
CY2023	allr	Deemed Dividend DeemedDividend	8392000	usd
CY2023Q2	allr	Deemed Dividend DeemedDividend	3328000	usd
CY2023	allr	Exchange Deemed Dividend ExchangeDeemedDividend	3959000	usd
CY2023Q4	allr	Exchange Of Shares ExchangeOfShares	50000	shares
CY2023	allr	Series A Preferred Stock SeriesAPreferredStock	5577	shares
CY2023Q3	allr	Preferredstockmodification Preferredstockmodification	206000	usd
CY2023	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	526000	usd
CY2023Q3	allr	Preferredstockmodification Preferredstockmodification	373000	usd
CY2023Q3	us-gaap	Preferred Units Outstanding PreferredUnitsOutstanding	4630	shares
CY2023Q3	us-gaap	Dividends Preferred Stock DividendsPreferredStock	5000000	usd
CY2023Q3	us-gaap	Dividends Cash DividendsCash	351000	usd
	allr	Cash Paid In Connection With Conversion Of Series A Preferred Stock CashPaidInConnectionWithConversionOfSeriesAPreferredStock	1511000	usd
CY2022Q3	allr	Cash Paid In Connection With Conversion Of Series A Preferred Stock CashPaidInConnectionWithConversionOfSeriesAPreferredStock	1646000	usd
CY2022Q1	us-gaap	Trading Gains Losses TradingGainsLosses	2500000	usd
CY2022Q1	allr	Percentage Of Deemed Dividend PercentageOfDeemedDividend	0.08	pure
CY2022	allr	Registration Delay Payment RegistrationDelayPayment	800000	usd
CY2023Q1	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	50000	shares
CY2023Q1	us-gaap	Payments For Proceeds From Previous Acquisition PaymentsForProceedsFromPreviousAcquisition	1200000	usd
CY2023Q1	us-gaap	Excess Stock Shares Issued ExcessStockSharesIssued	50000	shares
CY2023	allr	Expiration Of The Allowable Price Percentage ExpirationOfTheAllowablePricePercentage	0.02	pure
CY2023	allr	Partial Liquid Damage Interest Rate PartialLiquidDamageInterestRate	0.18	pure
CY2023Q2	us-gaap	Dividends Preferred Stock Cash DividendsPreferredStockCash	1200000	usd
CY2023Q2	allr	Debt Discount Opening DebtDiscountOpening	40000	usd
CY2023Q2	us-gaap	Preferred Stock Dividend Rate Percentage PreferredStockDividendRatePercentage	0.05	pure
CY2023Q2	allr	Exchange Of Series C Preferred Stock For Series A Preferred Stock Amount ExchangeOfSeriesCPreferredStockForSeriesAPreferredStockAmount	1446000	usd
CY2023Q4	allr	Fair Value Amount FairValueAmount	5200000	usd
CY2023	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	1240000	usd
CY2023Q4	us-gaap	Conversion Of Stock Amount Issued1 ConversionOfStockAmountIssued1	1931000	usd
	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	2015000	usd
CY2023Q3	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	9452667	shares
	allr	Cashless Redemption Of Exchange Warrants For Common Shares CashlessRedemptionOfExchangeWarrantsForCommonShares	1031000	usd
CY2023Q3	allr	Warrant Exchange Shares WarrantExchangeShares	5045446	shares
CY2023	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	820000	usd
CY2022	us-gaap	Assets Fair Value Adjustment AssetsFairValueAdjustment	374000	usd
CY2023Q4	allr	Warrant Exchange Shares WarrantExchangeShares	5045446	shares
CY2023Q1	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	the Company filed a Third Certificate of to the Certificate of Incorporation with the Delaware Secretary of State to effect a 1-for-35 share consolidation of our common stock on March 24, 2023 (“March Reverse Stock Split”). No fractional shares were issued in connection with the March Reverse Stock Split. If, as a result of the March Reverse Stock Split, a stockholder would otherwise have been entitled to a fractional share, each fractional share was rounded up to the next whole number.
CY2023Q4	us-gaap	Common Unit Authorized CommonUnitAuthorized	750500000	shares
CY2023Q4	us-gaap	Common Unit Issued CommonUnitIssued	750000000	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q2	us-gaap	Stockholders Equity Reverse Stock Split StockholdersEquityReverseStockSplit	Common Stock at a ratio between 1-for-15 and 1-for-50 (the “June Reverse Stock Split Proposal”). Upon stockholder approval, the Board of Directors determined a ratio of 1-for-40 for the reverse stock split (the “June Reverse Stock Split”).
CY2023Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	0.0001
CY2023Q2	us-gaap	Sale Of Stock Number Of Shares Issued In Transaction SaleOfStockNumberOfSharesIssuedInTransaction	71734	shares
CY2023Q2	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	71734	shares
CY2023Q2	allr	Prefunded Warrants Shares PrefundedWarrantsShares	178267	shares
CY2023Q2	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	7500000	usd
CY2023Q2	allr	Pre Fund Warrants PreFundWarrants	178267	shares
CY2023Q3	allr	Warrant Exercisable Term WarrantExercisableTerm	P5Y
CY2023	us-gaap	Proceeds From Issuance Of Private Placement ProceedsFromIssuanceOfPrivatePlacement	2962000000	usd
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	202000	usd
CY2023Q3	us-gaap	Warrant Exercise Price Decrease WarrantExercisePriceDecrease	1
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Plan Modification Incremental Compensation Cost ShareBasedCompensationArrangementByShareBasedPaymentAwardPlanModificationIncrementalCompensationCost	389000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	373000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	266000	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	1373534	shares
CY2023Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	143000	usd
CY2023Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	124000	usd
CY2023Q4	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	233000	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1
CY2023Q4	us-gaap	Share Price SharePrice	0.58
CY2023Q4	us-gaap	Share Price SharePrice	0.59
CY2023Q4	us-gaap	Share Price SharePrice	0.5
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0414	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0414	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0414	pure
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y7M6D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y7M9D
CY2023Q4	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y8M1D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.23	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.22	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.22	pure
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	1
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExercisePrice	34
CY2023Q4	us-gaap	Share Price SharePrice	0.55
CY2023Q3	us-gaap	Share Price SharePrice	1
CY2023Q3	us-gaap	Share Price SharePrice	3.4
CY2023Q2	us-gaap	Share Price SharePrice	20.4
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.0384	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.037	pure
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y9M25D
CY2023Q2	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.25	pure
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.27	pure
CY2023Q2	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.26	pure
CY2023Q4	us-gaap	Preferred Stock Redemption Price Per Share PreferredStockRedemptionPricePerShare	0.01
CY2022Q4	us-gaap	Preferred Units Description PreferredUnitsDescription	(i) 0.016 shares of Series B Preferred Stock for each outstanding share of common stock; and (ii) 1.744 shares of Series B Preferred Stock for each outstanding share of Series A Preferred Stock.
CY2023Q1	us-gaap	Preferred Stock Capital Shares Reserved For Future Issuance PreferredStockCapitalSharesReservedForFutureIssuance	190786	shares
CY2023	us-gaap	Partners Capital Account Units Sold In Public Offering PartnersCapitalAccountUnitsSoldInPublicOffering	71733	shares
CY2023	us-gaap	Proceeds From Issuance Of Debt ProceedsFromIssuanceOfDebt	6815000	usd
CY2023Q4	us-gaap	Common Stock Capital Shares Reserved For Future Issuance CommonStockCapitalSharesReservedForFutureIssuance	2444445	shares
CY2023Q4	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Each Warrant Or Right ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight	357223	shares
CY2022	us-gaap	Gross Profit GrossProfit	-2265000	usd
CY2023Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	5886934	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	11356	shares
CY2023Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2021	allr	Number Of Aggregate Shares Outstanding Percentage NumberOfAggregateSharesOutstandingPercentage	0.05	pure
CY2023	us-gaap	Share Based Compensation ShareBasedCompensation	-71000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	1752000	usd
CY2023	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	47000	usd
CY2022	us-gaap	Other Selling General And Administrative Expense OtherSellingGeneralAndAdministrativeExpense	1156000	usd
CY2023	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	24000	usd
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	596000	usd
CY2023Q4	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Stock Options EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedStockOptions	72000	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	483	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	9174
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y1M20D
CY2023	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	101	shares
CY2023	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	13996
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	382	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7876
CY2023	allr	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm	P3Y1M28D
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	341	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	5320
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P3Y2M4D
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	101	shares
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Nonvested Options Forfeited Number Of Shares SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsNonvestedOptionsForfeitedNumberOfShares	389	shares
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	7876
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested In Period Fair Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedInPeriodFairValue1	845000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Equity Instruments Other Than Options Vested In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsVestedInPeriodWeightedAverageGrantDateFairValue	1.19
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Period Increase Decrease Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingPeriodIncreaseDecreaseWeightedAverageExercisePrice	1.19
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2023Q4	us-gaap	Accounts Payable Other Current AccountsPayableOtherCurrent	3600000	usd
CY2023Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent	1300000	usd
CY2023Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	101000	usd
CY2023	us-gaap	Broadcasters License Agreement Commitments Description BroadcastersLicenseAgreementCommitmentsDescription	(i) $100 which has been paid; (ii) $50 within 10 days of execution of the fourth amendment which has been paid; (iii) $100 upon completion of a capital raise (paid on July 18, 2023); and (iv) $850 on or before March 1, 2024. As of the date of this filing, the Company is currently negotiating a fifth amendment to the extend the timeframe of periodic payments due.
CY2023	allr	Sales Milestone Payment SalesMilestonePayment	50000000	usd
CY2023	allr	Licensed Product Sales LicensedProductSales	1000000000	usd
CY2023	allr	Consideration Extension Payment ConsiderationExtensionPayment	1000000	usd
CY2019Q1	allr	Additional Amount AdditionalAmount	250000	usd
CY2022Q1	allr	Amended License Payment AmendedLicensePayment	338000	usd
CY2022Q1	allr	Milestone Payments MilestonePayments	3500000	usd
CY2021	us-gaap	Development Costs DevelopmentCosts	1264000	usd
CY2023	allr	Cancellation Of Company Liability CancellationOfCompanyLiability	1309000	usd
CY2023	allr	Agreement Payment AgreementPayment	338000	usd
CY2022Q2	us-gaap	Other Accrued Liabilities Noncurrent OtherAccruedLiabilitiesNoncurrent	338000	usd
CY2022Q2	us-gaap	Other Income OtherIncome	971000	usd
CY2022Q1	allr	Upfront Payment UpfrontPayment	250000	usd
CY2022Q2	allr	Upfront Payment Received UpfrontPaymentReceived	350000	usd
CY2023	allr	Milestone Payments MilestonePayments	1000000	usd
CY2023	us-gaap	Intercompany Agreements Description IntercompanyAgreementsDescription	Pursuant to the Oncoheroes Agreement the Company is also entitled to tiered royalties on aggregate net product sales (“Sales”) of between 7% and 12% on net sales of products as follows: 7% on Sales less than $100 million; 10% on Sales of greater than $100 million and less than $200 million; and 12% on Sales greater than $200 million.
CY2021Q3	us-gaap	Purchase Obligation PurchaseObligation	1000000	usd
CY2022Q1	allr	Other Income Gain On Sale Of Ip OtherIncomeGainOnSaleOfIP	459000	usd
CY2023	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2022	us-gaap	Effective Income Tax Rate Continuing Operations EffectiveIncomeTaxRateContinuingOperations	0.21	pure
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	2482000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign	3692000	usd
CY2023	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-73000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-260000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	1000	usd
CY2023	allr	Effective Income Tax Rate Reconciliation Tax Value Of Derivative Warrants EffectiveIncomeTaxRateReconciliationTaxValueOfDerivativeWarrants	-1187000	usd
CY2022	allr	Effective Income Tax Rate Reconciliation Tax Value Of Derivative Warrants EffectiveIncomeTaxRateReconciliationTaxValueOfDerivativeWarrants	-3597000	usd
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	559000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense Research And Development IncomeTaxReconciliationNondeductibleExpenseResearchAndDevelopment	754000	usd
CY2023	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	798000	usd
CY2022	us-gaap	Income Tax Reconciliation Tax Credits Research IncomeTaxReconciliationTaxCreditsResearch	609000	usd
CY2023	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	17000	usd
CY2022	us-gaap	Income Tax Reconciliation Other Adjustments IncomeTaxReconciliationOtherAdjustments	-1000	usd
CY2023	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	45000	usd
CY2022	us-gaap	Income Tax Reconciliation Prior Year Income Taxes IncomeTaxReconciliationPriorYearIncomeTaxes	-871000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	3524000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7044000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1521000	usd
CY2023	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-11818000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	-17579000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1521000	usd
CY2023Q4	allr	Deferred Tax Asset Property Plant And Equipment DeferredTaxAssetPropertyPlantAndEquipment	-25000	usd
CY2022Q4	allr	Deferred Tax Asset Property Plant And Equipment DeferredTaxAssetPropertyPlantAndEquipment	20000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1405000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Goodwill And Intangible Assets DeferredTaxAssetsGoodwillAndIntangibleAssets	1160000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	790000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost	1152000	usd
CY2023Q4	allr	Deferred Tax Assets Other Accruals DeferredTaxAssetsOtherAccruals	16000	usd
CY2022Q4	allr	Deferred Tax Assets Other Accruals DeferredTaxAssetsOtherAccruals	-44000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	16952000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Operating Loss Carryforwards DeferredTaxAssetsOperatingLossCarryforwards	12981000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	16328000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Gross DeferredTaxAssetsGross	12949000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	16774000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	13298000	usd
CY2023Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	446000	usd
CY2022Q4	us-gaap	Deferred Tax Liabilities DeferredTaxLiabilities	349000	usd
CY2023	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	83000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Enacted Tax Rate IncomeTaxReconciliationChangeInEnactedTaxRate	-1521000	usd
CY2023	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	83000	usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit	-1521000	usd
CY2023Q4	us-gaap	Deferred Tax Assets Other Tax Carryforwards DeferredTaxAssetsOtherTaxCarryforwards	78100000	usd
CY2023	us-gaap	Payments For Fees PaymentsForFees	127000	usd
CY2022	us-gaap	Payments For Fees PaymentsForFees	269000	usd
CY2023	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-20416000	usd
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-21051000	usd
CY2023	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	1990748	shares
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	6805	shares
CY2023	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-10.26
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-3093.42
CY2023	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	11071311	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	19173394	shares
CY2023	us-gaap	Dilutive Securities DilutiveSecurities	2667000	usd
CY2023	us-gaap	Earnings Per Share Diluted Undistributed EarningsPerShareDilutedUndistributed	0.1825
CY2023Q4	us-gaap	Warrants And Rights Outstanding WarrantsAndRightsOutstanding	2263000	usd
CY2023Q4	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	820000	usd
CY2023Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	-3083000	usd
CY2022Q4	us-gaap	Derivative Assets Liabilities At Fair Value Net DerivativeAssetsLiabilitiesAtFairValueNet	374000	usd
CY2022Q4	us-gaap	Derivative Fair Value Of Derivative Net DerivativeFairValueOfDerivativeNet	-374000	usd
CY2017Q1	us-gaap	Other Commitments Future Minimum Payments Remainder Of Fiscal Year OtherCommitmentsFutureMinimumPaymentsRemainderOfFiscalYear	500000	usd
CY2023	allr	Maximum Amount Of Development Milestone Payments Of Licensed Product MaximumAmountOfDevelopmentMilestonePaymentsOfLicensedProduct	500000000	usd
CY2023	allr	Maximum Amount Of Sales Milestone Payments Over First And Second Time Sales MaximumAmountOfSalesMilestonePaymentsOverFirstAndSecondTimeSales	1000000000	usd
CY2023Q4	allr	Aggregate Amount AggregateAmount	600000	usd
CY2023Q4	allr	Interest Payment Percentage InterestPaymentPercentage	0.90	pure
CY2023Q4	allr	Conversion Percentage ConversionPercentage	0.1999	pure
CY2023Q4	allr	Gross Proceeds Percentage GrossProceedsPercentage	1	pure
CY2023Q4	allr	Average Rate Percentage AverageRatePercentage	0.85	pure
CY2023	allr	Secured Note Purchaser And Holders Outstanding Percentage SecuredNotePurchaserAndHoldersOutstandingPercentage	0.5001	pure
CY2023Q4	us-gaap	Debt Current DebtCurrent	250000	usd
CY2023	us-gaap	Amortization Of Lease Incentives AmortizationOfLeaseIncentives	50000	usd
CY2023Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	4407221	shares
CY2023Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset		usd
CY2022Q4	us-gaap	Convertible Notes Payable Current ConvertibleNotesPayableCurrent		usd
CY2023Q4	us-gaap	Secured Debt Current SecuredDebtCurrent		usd
CY2023Q4	us-gaap	Convertible Long Term Notes Payable ConvertibleLongTermNotesPayable		usd
CY2023Q4	us-gaap	Redeemable Noncontrolling Interest Equity Carrying Amount RedeemableNoncontrollingInterestEquityCarryingAmount		usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue		usd
CY2023Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue		usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	allr	Loss On Modification Of Warrants LossOnModificationOfWarrants		usd
CY2023	us-gaap	Preferred Stock Dividends And Other Adjustments PreferredStockDividendsAndOtherAdjustments		usd
CY2023	us-gaap	Redeemable Preferred Stock Dividends RedeemablePreferredStockDividends		usd
CY2022	us-gaap	Other Preferred Stock Dividends And Adjustments OtherPreferredStockDividendsAndAdjustments		usd
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3093.42
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.26
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1990748	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6805	shares
CY2023	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues		usd
CY2023	allr	Stock Issued During Period Value Round Up Of Common Shares Issued As A Resulteverse Stock Splits StockIssuedDuringPeriodValueRoundUpOfCommonSharesIssuedAsAResulteverseStockSplits		usd
CY2023	us-gaap	Stock Redeemed Or Called During Period Value StockRedeemedOrCalledDuringPeriodValue		usd
CY2023	allr	Deemed Dividend On Modificationof Preferred Shares DeemedDividendOnModificationofPreferredShares		usd
CY2023	us-gaap	Gain Loss On Sale Of Investments GainLossOnSaleOfInvestments		usd
CY2023	us-gaap	Impairment Of Intangible Assets Finitelived ImpairmentOfIntangibleAssetsFinitelived		usd
CY2022	us-gaap	Other Noncash Income Expense OtherNoncashIncomeExpense		usd
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants		usd
CY2022	allr	Loss On Modification Of Warrants LossOnModificationOfWarrants		usd
CY2023	us-gaap	Gain Loss On Investments GainLossOnInvestments		usd
CY2022	us-gaap	Increase Decrease In Income Taxes Receivable IncreaseDecreaseInIncomeTaxesReceivable		usd
CY2023	us-gaap	Proceeds From Sale Of Investment Projects ProceedsFromSaleOfInvestmentProjects		usd
CY2023	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment		usd
CY2023	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities		usd
CY2022	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock		usd
CY2022	us-gaap	Repayments Of Secured Debt RepaymentsOfSecuredDebt		usd
CY2022	allr	Proceeds From Common Stock And Prefunded Warrant Issuance Net ProceedsFromCommonStockAndPrefundedWarrantIssuanceNet		usd
CY2022	allr	Proceeds From Warrants Exercised In Conjunction With Price Warrant Inducement ProceedsFromWarrantsExercisedInConjunctionWithPriceWarrantInducement		usd
CY2022	allr	Redemption Of Series A Preferred Stock RedemptionOfSeriesAPreferredStock		usd
CY2022	allr	Redemption Of Series B Preferred Stock RedemptionOfSeriesBPreferredStock		usd
CY2023	allr	Cash Paid In Connection With Conversion Of Series A Preferred Stock CashPaidInConnectionWithConversionOfSeriesAPreferredStock		usd
CY2023	allr	Penalty On Series A Preferred Stock Liability PenaltyOnSeriesAPreferredStockLiability		usd
CY2023	allr	Gain On Sale Of Ip GainOnSaleOfIP		usd
CY2022	allr	Issuance Of Series A Preferred Stock In Exchange For Series C Preferred Stock IssuanceOfSeriesAPreferredStockInExchangeForSeriesCPreferredStock		usd
CY2022	allr	Issuance Of Series A Preferred Stock To Extinguish Promissory Note IssuanceOfSeriesAPreferredStockToExtinguishPromissoryNote		usd
CY2022	allr	Redemption Of Series A Preferred Stock As Repayment Of Debt RedemptionOfSeriesAPreferredStockAsRepaymentOfDebt		usd
CY2022	allr	Deemed Dividend On Series C Convertible Preferred Stock And Accretion Of Series C Preferred Sh DeemedDividendOnSeriesCConvertiblePreferredStockAndAccretionOfSeriesCPreferredSh		usd
CY2022	allr	Deemed Dividend On Exchange Of Series C Preferred Stock For Series A Preferred Stock DeemedDividendOnExchangeOfSeriesCPreferredStockForSeriesAPreferredStock		usd
CY2023	allr	Deemed Dividend On Redemption Of Series B Preferred Stock DeemedDividendOnRedemptionOfSeriesBPreferredStock		usd
CY2023	allr	Conversion Of Floor Price Liability To Convertible Debt ConversionOfFloorPriceLiabilityToConvertibleDebt		usd
CY2023	allr	Reclassification Of Derivative Liabilities Related To Converted Preferred Stock ReclassificationOfDerivativeLiabilitiesRelatedToConvertedPreferredStock		usd
CY2023Q4	us-gaap	Deferred Costs Current DeferredCostsCurrent		usd
CY2023Q4	allr	Deferred Directors Officers Insurance Expense Current DeferredDirectorsOfficersInsuranceExpenseCurrent		usd
CY2022Q4	allr	Accruedinteresttonmilestoneliabilities Accruedinteresttonmilestoneliabilities		usd
CY2022Q4	us-gaap	Accrued Professional Fees Current AccruedProfessionalFeesCurrent		usd
CY2023	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P1Y9M
CY2023Q4	allr	Issued And Outstanding Options Expired Unexercised IssuedAndOutstandingOptionsExpiredUnexercised		shares
CY2023	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2022	us-gaap	Current Income Tax Expense Benefit CurrentIncomeTaxExpenseBenefit		usd
CY2023	allr	Adjustment Of Tax Concerning Previous Years AdjustmentOfTaxConcerningPreviousYears		usd
CY2022	allr	Adjustment Of Tax Concerning Previous Years AdjustmentOfTaxConcerningPreviousYears		usd
CY2023	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	1990748	shares
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	6805	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-3093.42
CY2023	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-10.26
CY2023	dei	Amendment Flag AmendmentFlag	false
CY2023	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2023	dei	Entity Central Index Key EntityCentralIndexKey	0001860657

Files In Submission

Name	View Source	Status
0001213900-24-020864-index-headers.html	Edgar Link	pending
0001213900-24-020864-index.html	Edgar Link	pending
0001213900-24-020864.txt	Edgar Link	pending
0001213900-24-020864-xbrl.zip	Edgar Link	pending
allr-20231231.xsd	Edgar Link	pending
ea0200752-10k_allarity.htm	Edgar Link	pending
ea0200752ex10-63_allarity.htm	Edgar Link	pending
ea0200752ex21_allarity.htm	Edgar Link	pending
ea0200752ex31-1_allarity.htm	Edgar Link	pending
ea0200752ex31-2_allarity.htm	Edgar Link	pending
allr-20231231_def.xml	Edgar Link	unprocessable
allr-20231231_lab.xml	Edgar Link	unprocessable
allr-20231231_pre.xml	Edgar Link	unprocessable
ea0200752-10k_allarity_htm.xml	Edgar Link	completed
ea0200752ex32-1_allarity.htm	Edgar Link	pending
ea0200752ex32-2_allarity.htm	Edgar Link	pending
ea0200752ex97_allarity.htm	Edgar Link	pending
ex10-63_001.jpg	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
image_008.jpg	Edgar Link	pending
image_009.jpg	Edgar Link	pending
image_010.jpg	Edgar Link	pending
image_011.jpg	Edgar Link	pending
image_012.jpg	Edgar Link	pending
image_013.jpg	Edgar Link	pending
image_014.jpg	Edgar Link	pending
image_015.jpg	Edgar Link	pending
image_016.jpg	Edgar Link	pending
image_017.jpg	Edgar Link	pending
image_018.jpg	Edgar Link	pending
image_019.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R64.htm	Edgar Link	pending
R65.htm	Edgar Link	pending
R66.htm	Edgar Link	pending
R67.htm	Edgar Link	pending
R68.htm	Edgar Link	pending
R69.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R70.htm	Edgar Link	pending
R71.htm	Edgar Link	pending
R72.htm	Edgar Link	pending
R73.htm	Edgar Link	pending
R74.htm	Edgar Link	pending
R75.htm	Edgar Link	pending
R76.htm	Edgar Link	pending
R77.htm	Edgar Link	pending
R78.htm	Edgar Link	pending
R79.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R80.htm	Edgar Link	pending
R81.htm	Edgar Link	pending
R82.htm	Edgar Link	pending
R83.htm	Edgar Link	pending
R84.htm	Edgar Link	pending
R85.htm	Edgar Link	pending
R86.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
FilingSummary.xml	Edgar Link	unprocessable
allr-20231231_cal.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ALLR
Allarity Therapeutics, Inc. Stock $allr

2024 Q1 Form 10-K Financial Statement

#000121390024020864 Filed on March 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLR Allarity Therapeutics, Inc. Stock $allr

2024 Q1 Form 10-K Financial Statement

#000121390024020864 Filed on March 08, 2024

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ALLR
Allarity Therapeutics, Inc. Stock $allr